超声
Zeta电位
渗透
Box-Behnken设计
粒径
肺表面活性物质
析因实验
药物输送
体内
化学
体外
固体脂质纳米粒
最大值
药理学
色谱法
剂型
透皮
PLGA公司
材料科学
离体
纳米颗粒
生物利用度
响应面法
控制释放
泊洛沙姆
中心组合设计
化学工程
毒品携带者
壳聚糖
生物医学工程
纳米技术
药代动力学
生物化学
医学
数学
生物技术
统计
物理化学
膜
生物
作者
Arisha Mahmood,Vamshi Krishna Rapalli,Srividya Gorantla,Tejashree Waghule,Gautam Singhvi
标识
DOI:10.1007/s13346-021-00986-7
摘要
The present study is concerned with the QbD-based design and development of luliconazole-loaded nanostructured lipid carriers (NLCs) hydrogel for enhanced skin retention and permeation. The NLCs formulation was optimized employing a 3-factor, 3-level Box-Behnken design. The effect of formulation variable lipid content, surfactant concentration, and sonication time was studied on particle size and % EE. The optimized formulation exhibited particle size of 86.480 ± 0.799 nm; 0.213 ± 0.004 PDI, ≥ − 10 mV zeta potential and 85.770 ± 0.503% EE. The in vitro release studies revealed sustained release of NLCs up to 42 h. The designed formulation showed desirable occlusivity, spreadability (0.748 ± 0.160), extrudability (3.130 ± 1.570), and the assay was found to be 99.520 ± 0.890%. The dermatokinetics assessment revealed the Cmax Skin to be ~ 2-fold higher and AUC0–24 to be ~ 3-fold higher in the epidermis and dermis of NLCs loaded gel in contrast with the marketed cream. The Tmax of both the formulations was found to be 6 h in the epidermis and dermis. The obtained results suggested that luliconazole NLCs can serve as a promising formulation to enhance luliconazole’s antifungal activity and also in increasing patient compliance by reducing the frequency of application.
科研通智能强力驱动
Strongly Powered by AbleSci AI